Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SVN 5367/M 57KLH peptide vaccine - MimiVax

Next Previous
Drug Profile

SVN 5367/M 57KLH peptide vaccine - MimiVax

Alternative Names: SurVaxM; Survivin peptide mimic vaccine - MimiVax; Survivin-targeted peptide vaccine - MimiVax; SVN53-67/M57-KLH peptide vaccine - MimiVax

Latest Information Update: 16 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roswell Park Cancer Institute
  • Developer MimiVax; National Cancer Institute (USA); Roswell Park Cancer Institute
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • No development reported Autoimmune disorders; Glioma; Multiple myeloma; Neuroendocrine tumours

Most Recent Events

  • 15 Jan 2024 Roswell Park Cancer Institute plans a phase II trial for Neuroendocrine tumours (Metastatic disease) in USA (SC) (NCT06202066)
  • 12 Oct 2023 SVN 5367/M 57KLH peptide vaccine - MimiVax receives Fast Track designation for Glioblastoma [SC,Injection] (Newly diagnosed) in USA
  • 28 May 2023 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top